Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
STUDIO ALICE, 6% Decrease in Ordinary Profit for The Current Fiscal Year
2305 STUDIO ALICE Co.,Ltd. 【J-GAAP】
Earnings ReportSTUDIO ALICE Co.,Ltd. <2305> [TSE Std] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the fiscal year ending February 2025 expanded 31.4% from the previous period to 3.05 billion yen. However, for the fiscal year ending February 2026, the profit is expected to decrease by 5.9% from the previous period to 2.87 billion yen.
In the most recent three-month period, from December to February (4Q), the consolidated ordinary profit increased 76.8% from the same period last year, reaching 0.69 billion yen. The operating profit margin significantly improved from 4.1% in the same period last year to 7.9%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2023 | 38,564 | 4,017 | 4,009 | 2,257 | 132.9 | 70 | Apr 13, 2023 | J-GAAP |
Feb, 2024 | 36,396 | 2,283 | 2,322 | 1,157 | 68.2 | 70 | Apr 12, 2024 | J-GAAP |
Feb, 2025 | 35,598 | 3,021 | 3,051 | 1,365 | 80.4 | 50 | Apr 14, 2025 | J-GAAP |
YoY | -2.2% | +32.3% | +31.4% | +18.0% | +17.9% |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2025 Guidance | 36,800 | 2,670 | 2,640 | 1,250 | 73.6 | 50 | Apr 12, 2024 | J-GAAP |
Feb, 2025 Results | 35,598 | 3,021 | 3,051 | 1,365 | 80.4 | 50 | Apr 14, 2025 | J-GAAP |
Revision Rate | -3.3% | +13.1% | +15.6% | +9.2% | +9.2% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar - Aug, 2024 | 15,363 | -531 | -508 | -598 | -35.2 | 0 | Oct 11, 2024 | J-GAAP |
Mar - Aug, 2025 Guidance | ー | ー | ー | ー | - | 0 | Apr 14, 2025 | J-GAAP |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2024 | 36,396 | 2,283 | 2,322 | 1,157 | 68.2 | 70 | Apr 12, 2024 | J-GAAP |
Feb, 2025 | 35,598 | 3,021 | 3,051 | 1,365 | 80.4 | 50 | Apr 14, 2025 | J-GAAP |
Feb, 2026 Guidance | 33,780 | 2,870 | 2,870 | 1,450 | 85.4 | 50 | Apr 14, 2025 | J-GAAP |
YoY | -5.1% | -5.0% | -5.9% | +6.2% | +6.2% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 8,980 | 370 | 393 | 31 | 1.8 | 4.1 | Apr 12, 2024 | J-GAAP |
Mar - May, 2024 | 8,134 | -128 | -132 | -276 | -16.3 | -1.6 | Jul 11, 2024 | J-GAAP |
Jun - Aug, 2024 | 7,229 | -403 | -376 | -322 | -19.0 | -5.6 | Oct 11, 2024 | J-GAAP |
Sep - Nov, 2024 | 11,472 | 2,859 | 2,864 | 1,761 | 103.7 | 24.9 | Jan 10, 2025 | J-GAAP |
Dec - Feb, 2024 | 8,763 | 693 | 695 | 202 | 11.9 | 7.9 | Apr 14, 2025 | J-GAAP |
YoY | -2.4% | +87.3% | +76.8% | +551.6% | +550.3% |
Related Articles
Lacto Japan, Dec-Feb (1Q) Ordinary Profit Increases by 43%
SMN, Last Fiscal Year Net Income Revised Upward by 93%
DOUTOR NICHIRES, 12% Increase in Ordinary Profit, Record High for The First Time in Nine Years, Increased Previous Year's Dividend by 2 yen, This Fiscal Year to Increase Dividend by 4 yen
DEMAE-CAN, First Half Ordinary Profit Loss Narrows, Dec-Feb Ordinary Profit Loss Narrows
Copa Corp, Net Income/Loss Unexpectedly Turn to Loss for Last Fiscal Year, The Current Fiscal Year's Net Income to Narrow
COSMOS Pharma, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 30%, Dec-Feb Ordinary Profit Increases by 40%
FP Partner, Dec-Feb (1Q) Ordinary Profit Decreases by 42%
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%